文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

早产儿视网膜病变的蛋白质组学特征:Mega Donna Mega 随机临床试验的二次分析

Proteomic Profile in Retinopathy of Prematurity: A Secondary Analysis of the Mega Donna Mega Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2026-01-01

该研究为瑞典3所大学医院开展的Mega Donna Mega双盲随机临床试验的事后探索性分析,纳入177例胎龄小于28周的极早产儿,采用Olink靶向蛋白质组学检测538种分析物。结果显示,109种蛋白在生后第一个月的纵向变化与严重ROP相关,其中FGF-21和tPA在生后最初数天的快速上升与严重ROP关联最强;未观察到AA/DHA补充与蛋白质组相关。

要点

  • 生后第一个月109种蛋白的纵向变化与严重ROP相关,涉及免疫反应、凋亡、凝血和脂代谢。
  • FGF-21(β=0.68;95%CI 0.39-0.97;Q=.002)与tPA(β=0.21;95%CI 0.13-0.29;Q<.001)生后早期快速上升与严重ROP关联最强。
  • 未观察到AA/DHA补充与蛋白质组之间存在关联。

核心结论

  • 在极早产儿中,生后最初数天FGF-21水平的快速上升与严重ROP的发生强烈相关。
  • 这些发现提示,改善生物能量状态的早期干预可能有助于预防严重ROP。

研究设计与样本

  • 研究为Mega Donna Mega双盲随机临床试验的探索性事后分析,采用Olink靶向邻近延伸分析蛋白质组学,覆盖538种分析物。
  • 研究地点为瑞典3所大学医院,纳入2016至2019年出生、胎龄小于28周的极早产儿,数据分析时间为2025年1月至3月。
  • 共纳入177例极早产儿(平均[SD]胎龄25.6[1.4]周;男性100例[56.5%]),其中50例(28.2%)发生严重ROP。
  • 所有婴儿接受标准营养,其中一半从出生至矫正足月龄接受肠内脂质补充AA/DHA(100/50 mg/kg/天)。
  • 采用混合模型分析生后第一个月的纵向蛋白谱,校正胎龄、研究中心和AA/DHA补充,并检验严重ROP与生后日龄的交互作用。

主要发现

  • 538种纵向分析的蛋白中,生后第一个月有109种蛋白谱与严重ROP相关,涉及免疫反应、凋亡过程、血液凝固和脂质代谢。
  • 与严重ROP关联最显著的是生后最初数天成纤维细胞生长因子21(FGF-21;β=0.68;95%CI 0.39-0.97;Q=.002)和组织型纤溶酶原激活物(tPA;β=0.21;95%CI 0.13-0.29;Q<.001)的快速上升。
  • 生后第一周血清FGF-21水平升高与更低胎龄、更低出生体重、更低肠内能量摄入及更多机械通气天数相关。
  • 未观察到AA/DHA补充与蛋白质组之间的关联。

临床怎么用

  • 对于极早产儿,生后早期FGF-21和tPA的快速上升可能提示严重ROP风险,可作为潜在监测靶点。
  • AA/DHA补充未显示与蛋白质组相关,不支持其通过改变该蛋白谱来预防严重ROP。

局限性

  • 本研究为事后探索性分析,结果需进一步验证。
  • 研究仅纳入瑞典3所大学医院的极早产儿,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Identifying early proteomic profiles in infants who develop severe retinopathy of prematurity (ROP) may reveal targets for preventive interventions to reduce retinal vessel loss and the subsequent risk of severe ROP. OBJECTIVE: To assess early longitudinal profiles of blood protein levels in preterm infants with or without severe ROP and the effect of arachidonic acid (AA) and docosahexaenoic acid (DHA) supplementation. DESIGN, SETTING, AND PARTICIPANTS: This was an exploratory, post hoc analysis of serum proteome profiles in preterm infants in the double-masked Mega Donna Mega (MDM) randomized clinical trial using targeted Olink Proximity Extension Assay proteomics covering 538 analytes. The setting was 3 university hospitals in Sweden and included extremely preterm infants born before 28 weeks of gestational age (GA), from 2016 to 2019. Data were analyzed from January to March 2025. EXPOSURES: All infants received standard nutrition; additionally, half received enteral lipid supplementation with AA/DHA (100/50 mg/kg per day) from birth to term equivalent age. MAIN OUTCOMES AND MEASURES: Longitudinal protein profiles during the first month of life were examined using mixed models for repeated measures, adjusted for GA, study center, and AA/DHA supplementation, and tested for the interaction between severe ROP (stage ≥3 and/or treated) and postnatal age. RESULTS: A total of 177 extremely preterm infants (mean [SD] GA, 25.6 [1.4] weeks; 100 male [56.5%]) were included, of whom 50 (28.2%) developed severe ROP. Of 538 longitudinal analyzed proteins, 109 protein profiles in the first month of life associated with severe ROP, proteins related to immune response, apoptotic processes, blood coagulation, and lipid metabolism. The most pronounced association with severe ROP was a fast rise in fibroblast growth factor 21 (FGF-21; β = 0.68; 95% CI, 0.39-0.97; Q =.002) and tissue plasminogen activator (tPA; β = 0.21; 95% CI, 0.13-0.29; Q <.001) during the first postnatal days. The increase in serum FGF-21 level in the first week of life was associated with lower GA, lower birth weight, low enteral energy intake, and more days receiving mechanical ventilation. No association was observed between AA/DHA supplementation and the proteome. CONCLUSIONS AND RELEVANCE: In this post hoc exploratory analysis of data from the MDM randomized clinical trial, a fast rise in FGF-21 levels, a metabolic stress-induced hormone, during the first postnatal days was strongly associated with the development of severe ROP in extremely preterm infants. These findings suggest that early interventions improving bioenergetic status may help prevent severe ROP. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03201588.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Lundgren P, Danielsson H, Panwar MB, et al. Proteomic Profile in Retinopathy of Prematurity: A Secondary Analysis of the Mega Donna Mega Randomized Clinical Trial. JAMA Ophthalmol. 2026. PMID: 41505112. doi:10.1001/jamaophthalmol.2025.5594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。